10x Genomics, a global leader in single cell and spatial biology, has announced the signing of a definitive agreement to acquire Scale Biosciences, Inc., a pioneer in scalable and innovative single cell analysis. This acquisition brings 10x access to Scale’s groundbreaking inventions and technologies, strengthening its Chromium platform and furthering its mission to make single cell analysis more powerful, affordable, and widely accessible to researchers worldwide.
Founded by a multidisciplinary team of experts in next-generation sequencing, genomics, and bioinformatics, Scale Biosciences has developed unique advancements in combinatorial indexing and quantum barcoding—key breakthroughs in scaling single cell analysis. These innovations will now be integrated into 10x’s product development roadmap. Scale’s scientific founders—Prof. Garry Nolan (Stanford University), Profs. Jay Shendure and Cole Trapnell (University of Washington), and Frank Steemers—will join 10x as advisors.
"At 10x, we’re driven to create a future where single cell analysis is routine, accessible, and scalable beyond anything previously imagined," said Serge Saxonov, CEO of 10x Genomics. "This acquisition moves us closer to that vision. By merging Scale’s technologies with our global platform, we’ll expand the capabilities of both existing and upcoming products."
The integration of Scale’s innovations is expected to enable more researchers to conduct high-throughput studies, preserve high-quality multiomic data, and accelerate scientific discoveries. The acquisition aligns with 10x’s ambitious multi-year roadmap aimed at dramatically increasing the number of cells and samples that can be analyzed.
Prof. Garry Nolan, PhD, co-founder of Scale Biosciences, noted: "These technologies were created to make single cell analysis vastly more scalable and accessible. With 10x’s innovation capabilities, their impact will grow exponentially—fueling the AI-driven breakthroughs needed in modern medicine."
Giovanna Prout, President and CEO of Scale Biosciences, added: "We’re proud of our achievements in advancing biological understanding. Joining forces with 10x will help our technology reach new markets, emerging applications, and a broader global research community."
10x has committed to supporting Scale’s existing customers, ongoing experiments, and initiatives like the 100 Million Cell Challenge and Billion Cells Project. Several key Scale products will remain available on the market.